



# Association of albumin to creatinine ratio with urinary arsenic and metal exposure: evidence from NHANES 2015–2016

Humairat H Rahman<sup>1</sup> · Danielle Niemann<sup>2</sup> · Stuart H. Munson-McGee<sup>3</sup>

Received: 16 February 2021 / Accepted: 5 October 2021 / Published online: 13 October 2021  
© The Author(s), under exclusive licence to Springer Nature B.V. 2021

## Abstract

**Purpose** Urinary metals can be used to identify metal exposure in humans from various sources in the environment. Decreased renal function and cardiovascular dysfunction may occur due to low levels of metal exposure in the general population. The purpose of this study is to assess the association between urinary arsenic and metals and a higher albumin to creatinine ratio (ACR) among adults in the general US population.

**Methods** We conducted a cross sectional analyses using the 2015–2016 National Health and Nutrition Examination Survey (NHANES) dataset. Multiple linear logistic models were used to examine the association between 21 urinary arsenic and metal concentrations (arsenous acid, arsenic acid, arsenobetaine, arsenocholine, dimethylarsinic acid, monomethylarsonic acid, total arsenic, mercury, barium, cadmium, cobalt, cesium, molybdenum, manganese, lead, antimony, tin, strontium, thallium, tungsten, uranium) and increased ACR ( $\geq 30$  mg/g).

**Results** The sample included 4122 adults, of whom approximately 9.4% of males and 10.7% females had increased ACRs. The exposure included urinary arsenic compounds (7) and urinary metal compounds (14) at or above the limit of detection. Urinary dimethylarsinic acid [OR 38.9, 95% CI 3.6–414.6], urinary monomethylarsonic acid [OR 18.6, 95% CI 1.1–308.2], urinary cadmium [OR 11.9, 95% CI 1.2–122.0], urinary cesium [OR 17.0, 95% CI 2.7–105.8], and urinary antimony [OR 10.7, 95% CI 2.2–51.3] were associated with an increased ACR. No other urinary metals were significantly associated with increased ACR.

**Conclusion** Increased ACR was positively associated with urinary dimethylarsinic acid, monomethylarsonic acid, cadmium, cesium, and antimony.

**Keywords** Albuminuria · Urinary arsenic exposure · Urinary metal exposure · Cadmium · Antimony · NHANES

## Introduction

Metals are widely used and extensively disseminated in the environment. The toxicity of metals in human health is a clinical and public health concern. Toxic reactions can occur when excess amounts of metal are present in the human body resulting in pathology to multiple organs [1, 2]. Arsenic is found naturally in the soil and is considered toxic, the most

common exposure occurs through food and water consumption [3]. Arsenic is a group 1 human carcinogen that has been associated with kidney, liver, skin, lung, and bladder cancers and is the second leading water borne cause of mortality [4]. Exposure to low levels of arsenic, cadmium, lead, and mercury may increase risks of cancer, kidney disease, cardiovascular and skeletal disease [1, 5–9]. Environmental exposures to low-level lead, mercury, and cadmium are widespread, particularly in industrialized countries. These metals can be present in cigarettes, gasoline, air, and foods, including seafood and foods grown in contaminated soil [10]. Arsenic exposure occurs in people that rely on well water and foods such as apple juice and rice. Workers are at risk with co-exposures of arsenic and wood dust, silica, and asbestos [11].

The kidney is a target organ for metals, which can accumulate in the nephron leading to changes in morphology and

✉ Humairat H. Rahman  
hrahman@nmsu.edu

<sup>1</sup> New Mexico State University, Las Cruces, NM 88003, USA

<sup>2</sup> Burrell College of Osteopathic Medicine, Las Cruces, NM, USA

<sup>3</sup> Data Forward Analytics, LLC, Principal, Las Cruces, NM, USA

function, thought to be due to oxidative stress. The proximal tubule is known as a main site of metal accumulation and injury in addition to the distal nephron, glomeruli, and vessels [12]. The 2012 Kidney Disease Improving Global Outcome (KDIGO) guidelines define chronic kidney disease (CKD) as one or more markers of kidney damage or a decreased glomerular filtration rate (GFR) ( $< 60 \text{ ml/min/1.73 m}^2$ ) for greater than 3 months. Markers of kidney damage include: albuminuria (albumin excretion rate (AER)  $\geq 30 \text{ mg/24 h}$  or  $\text{ACR} \geq 30 \text{ mg/g}$ ), urine sediment abnormalities, electrolyte and other abnormalities due to tubular disorders, abnormalities detected by histology, structural abnormalities detected by imaging, and history of kidney transplantation [13]. The albumin to creatinine ratio (ACR) is beneficial in that it can be measured using a spot urine sample to detect abnormal albumin without waiting 24 h. Calculating the ratio improves sensitivity and is not affected by dilute or concentrated urine, correcting for variations in hydration [14, 15]. The National Health and Nutrition Examination Survey (NHANES) dataset provides ACR data on participants throughout the United States (US) using spot urine samples but does not track participants over the period of 3 months to establish a diagnosis of CKD [16]. GFR categorizes CKD into five stages, however, there can be error due to calibration of GFR measurements, selection of the GFR formula, and variations in serum creatinine [17].

The kidney is the major organ of excretion of metals, including arsenic. Several studies have investigated the adverse effects of arsenic toxicity on renal function. Since albuminuria is an early marker for glomerular damage and can lead to change in the GFR, several studies observed albuminuria as the outcome of interest for kidney function [18]. Increased albuminuria can identify the need for an immediate therapeutic intervention [19].

The cause of metal exposure in the general population and the association of nephrotoxicity is unknown [20]. Some studies found links between increased blood lead and cadmium, and increased urinary lead and chromium, with decreased GFR [21–25]. In addition, cesium is eliminated through the kidneys and studies have shown higher concentrations in the kidneys [26]. However, research is lacking studying the effect of cesium on kidney disease.

The prevalence of CKD is estimated to be 8–16% worldwide, with diabetes being the most common cause. The number of end stage renal disease (ESRD) cases has been increasing disproportionately in developing countries; increasing hypertension and diabetes will further enhance the prevalence of ESRD. CKD more commonly leads to death than ESRD, likely due to accelerated rates of atherosclerosis and heart failure. Therefore, those with CKD are in the highest risk group for cardiovascular disease. Furthermore, CKD imposes a substantial economic burden on patients. 2–3% of healthcare expenditures in developed

countries go towards providing treatment for patients with ESRD. In 2010, costs for ESRD accounted for 6.3% of the Medicare budget. In 2007, US Medicare expenditures exceeded \$60 billion for CKD [27].

The goal of the present study is to investigate the relationship between arsenic and metal exposure including: arsenous acid, arsenic acid, arsenobetaine, arsenocholine, dimethylarsinic acid (DMA), monomethylarsonic acid (MMA), total arsenic, mercury, barium, cadmium, cobalt, cesium, molybdenum, manganese, lead, antimony, tin, strontium, thallium, tungsten, and uranium, as measured in urine, with the presence of albuminuria in US population using ACR.

## Methods

### Data sources

The data for this project was taken from the 2015–2016 NHANES data set, a long-standing study conducted by the National Center for Health Statistics (NCHS), a part of the Centers for Disease Control and Prevention (CDC). It combines interviews and physical examinations of children and adults throughout the US to determine the health and nutritional status of the US [28].

The ACR used to create the response variable came from the NHANES data file ALB\_CR\_I [29]. The NHANES data files for urinary arsenic and urinary metals, used as the variate data, were: UAS\_I—Speciated urinary arsenic, UTAS\_I—Total Urinary arsenic, UMS\_I—Urinary metals, and UHG\_I—Urinary mercury [16, 30–32]. The data for the covariates came from the following NHANES data files: ALQ\_I—Alcohol consumption, BMX\_I—Body mass index, DEMO\_I—Demographic data, BPQ\_I—Blood pressure questionnaire [33–36]. NHANES was approved by the Research Ethics Review Board of the National Center for Health Statistics. As this is a public-use dataset, this study was exempt from additional review by an institutional review board.

### Data cleaning

The data cleaning consisted of four primary steps: (1) removing all missing responses and those for pregnant women, (2) categorizing the continuous covariate variables, (3) normalizing the concentration of the urinary chemical species by the creatinine concentration, and (4) creating the binary categorical variable for albuminuria. Missing responses in the demographic data, BMI, serum creatinine, and alcohol consumption were removed and the reduced data set was used for all subsequent modeling. If any one of these variables was missing, the entire response was eliminated. Missing responses for the urinary arsenic and urinary metals

were removed from the complete data set just prior to creation of the logit regression model.

The continuous variables age, family income to poverty ratio (FIPR), and body mass index (BMI) were converted into categorical factors. Age was converted into a three-level categorical variable with the levels  $20 \leq \text{age}1 \leq 40$ ,  $41 \leq \text{age}2 \leq 65$  and  $65 < \text{age}3$  [3]. FIPR was converted into a three-level categorical variable:  $0 \leq \text{FIPR}1 \leq 130\%$ ,  $130\% \leq \text{FIPR}2 \leq 350\%$  and  $350\% < \text{FIPR}3$ . BMI was converted into a four-level categorical variable with *underweight* :  $\text{BMI} < 18.5$ , *normalweight* :  $18.5 \leq \text{BMI} < 24.9$ , *overweight* :  $24.9 \leq \text{BMI} < 30.0$ , and *obese* :  $30.0 \leq \text{BMI}$  per the CDC definitions [37].

Natural variation in urine dilution, due to variations in the urine flow rate (UFR), was addressed by taking the urinary arsenic and metals species and dividing them by the creatinine concentration [38]. No attempt was made to make the concentration units consistent, the values provided in the NHANES data were used directly. Once the concentration had been normalized, they were then  $\log_{10}$  transformed to create a more nearly normal distribution of the concentrations.

CKD is defined as a urine ACR  $\geq 30$  mg/g over 3 months, defined in the most recent KDIGO 2012 guidelines [23]. Urinary albumin was measured in spot urine samples by solid-phase fluorescence immunoassay. The lower limit of detection for the assay was  $0.3 \mu\text{g/mL}$ . Urinary creatinine was measured by the modified kinetic Jaffé method. The categorical binary variable for albuminuria was  $\text{ACR} \geq 30$  mg/g [39]. Only single albumin and creatinine levels were available in the NHANES dataset, therefore variation during the day and among different days was not assessed.

Dose–response relationships for the various urinary species and albuminuria were also investigated. For each normalized urinary species, a 5-level categorical variable was created. The first level included those below the lower limit of detection (LLoD). The remaining four levels were separated by the quantiles of the responses that were above the LLoD. One at a time these new categorical variables were used in multivariate linear logit regression models and the regression coefficients converted into odds ratios. The logit regression included the main effects of the same covariates as used above. For the concentration of arsenic and metal, the quantiles of urinary species normalized concentrations were calculated for the unweighted sample.

## Statistical analyses

The statistical analysis was done in R version 3.6.3 using programs from the *survey* package to account for the complex design used in the construction of the NHANES survey [40–43]. The workhorse package used in this study was

the *survey* package which was also used in illustrations of NHANES data analysis provided by the CDC [44]. Specifically, from the *survey* package the functions *svyby*, *svymean*, *svyttest*, *svydesign*, and *svyglm* were used to calculate the unweighted occurrences of responses, the weighted mean of the responses, the weighted pairwise *t*-tests of the responses, the survey design object, and the logit regression models, respectively. Additional R functions and packages used to simplify the programming included: the function *nhanes\_load\_data* in the package *RNHANES* was used to download the data files from the NHANES website and store them locally as comma separated values (\*.csv) files [45, 46].

Using functions from the *survey* package, all analyses were weighted using the NHANES data on the survey design to account for the effects of design stratification and clustering. The descriptive statistics were calculated to determine the distribution of the participants across the covariates gender, ethnicity, highest level of education attained, marital status, age, FIPR, BMI, urinary cotinine concentration (a marker for smoking), and alcohol consumption. Multivariate logistic regression, with the covariates as cofactors, was used to compute the odds ratio (ORs) and their 95% confidence intervals (CI) for the association between albuminuria and the presence of urinary metals or arsenic species. Separate models were constructed for each metal or arsenic species.

## Results

### Preliminary data review: covariate factors

Given in Table 1 is a summary of the covariates used in this analysis. From the data presented in Table 1, the factors gender, serum cotinine, and alcohol consumption do not appear to significantly affect the percentage of respondents with albuminuria. The remaining factors do appear to affect the percentage of respondents with albuminuria in the following manners: ethnicity—non-Hispanic blacks have a higher likelihood of albuminuria than do the other ethnic groups, education—generally, the more education one has, the lower the likelihood of having albuminuria, marital status—those who are divorced, widowed, or separated have a higher likelihood of having albuminuria, age—the older one is the higher the likelihood of having albuminuria, FIPR—the higher one's income ratio the lower the likelihood of having albuminuria, and BMI—the higher one's BMI the higher the likelihood of having albuminuria. Table 2 revealed that age categories 40–64 years and 65 and over were significant at the  $\alpha = 0.05$  level for an increased likelihood of albuminuria. In addition, a BMI of  $> 30.0$ , or obese, was also significant for an increased likelihood of having albuminuria.

**Table 1** Summary statistics for demographics related to albuminuria

Category	Variable	Sample statistics				Population statistics		
		<i>N</i>	%	<i>N<sub>A</sub></i>	% <sub>A</sub>		% <sub>A</sub>	
Gender	Male	2042	49.6	262	12.8%	a	9.4%	a
	Female	2075	50.4	259	12.5%	a	10.7%	a
Ethnicity	Mexican American	724	17.6	104	14.4%	ab	11.2%	ab
	Other Hispanic	527	12.8	50	9.5%	ab	7.4%	a
	Non-Hispanic White	1466	35.6	186	12.7%	ab	9.6%	ab
	Non-Hispanic Black	822	20.0	121	14.7%	a	13.5%	b
	Non-Hispanic Asian	429	10.4	37	8.6%	b	8.0%	ab
	Other	149	3.6	23	15.4%	ab	14.1%	ab
Education	No high school	455	11.1	87	19.1%	b	16.1%	a
	Some high school	451	11.0	65	14.4%	ab	14.8%	a
	High school graduate	915	22.2	133	14.5%	ab	11.4%	ab
	Some college	1256	30.5	143	11.4%	ac	8.8%	b
	College graduate	1040	25.3	93	8.9%	c	8.6%	b
Marital status	Married	2094	50.9	253	12.1%	bd	9.5%	cd
	Widowed	291	7.1	72	24.7%	a	18.7%	a
	Divorced	449	10.9	74	16.5%	b	13.9%	abc
	Separated	139	3.4	23	16.5%	abcd	18.9%	ab
	Never married	743	18.0	59	7.9%	c	5.9%	d
	Living with partner	401	9.7	40	10.0%	cd	9.8%	bcd
Age	20–44	1349	32.8	87	6.4%	c	5.5%	c
	45–59	1797	43.6	206	11.5%	a	9.1%	a
	60 and older	971	23.6	228	23.5%	b	20.3%	b
FIPR	Less than 1.5	1302	31.6	223	17.1%	c	15.6%	c
	1.5–3.5	1656	40.2	216	13.0%	a	11.1%	a
	Over 3.5	1159	28.2	82	7.1%	b	6.7%	b
BMI	Normal weight	1029	25.0	108	10.5%	b	7.8%	b
	Underweight	57	1.4	6	10.5%	ab	12.7%	ab
	Overweight	1336	32.5	163	12.2%	ab	9.9%	ab
	Obese	1695	41.2	244	14.4%	a	11.6%	a
Cotinine concentration	Below LLoD	1380	33.5	167	12.1%	a	9.0%	a
	Above LLoD	2737	66.5	354	12.9%	a	10.7%	a
Alcohol CONSUMPTION	12 drinks or fewer	2863	69.5	358	12.5%	a	10.2%	a
	More than 12 drinks	1254	30.5	163	13.0%	a	9.8%	a

*N* number of respondents in the study, % percentage of respondents in the study, *N<sub>A</sub>* number of respondents in the study or population who have albuminuria. Values within the same category followed by the same letter are not statistically different at the  $\alpha=0.05$  level. For the categories with only two levels, this was determined using a  $\chi^2$  test on the appropriate contingency table. For categories with more than two levels, this was determined using a Tukey analysis based on a linear model using only the variables within that category as the independent factors

Five urinary metals were found to have a positive association with albuminuria at the  $\alpha=0.05$  level as seen in Table 3. Among speciated arsenic, DMA (OR 38.9, 95% CI 3.6–414.6) and MMA (OR 18.6, 95% CI 1.1–308.2) had the highest odds ratios among the significant metals. Among the other metal compounds, cadmium (OR 11.9, 95% CI 1.2–122.0), cesium (OR 17.0, 95% CI 2.7–105.8), and antimony (OR 10.7, 95% CI 2.2–51.3) had a positive association with increased ACR, or albuminuria.

Concentration profiles in the form of quantiles for the various urinary arsenic and metal species are given in Table 4. There were detectable levels of arsenic in about 3% to 100% of the people in the sample depending on the specific arsenic species being considered. Detectable levels of the metal species were higher, ranging from about 30% to 100% of the individuals in the sample. For all species, the distribution of levels detected in the individuals was highly non-normal with a significant tail at higher concentrations.

**Table 2** Demographic model  $\log_{10}$  odds ratios (OR) and their 95% confidence intervals (CI) related to albuminuria from the logit regression models using only the main effects of the covariates for nine categories

Category	Variable	OR	95% CI
Gender	Male		
	Female	1.366	0.598–3.120
Ethnicity	Mexican American		
	Other Hispanic	0.365	0.125–1.065
	Non-Hispanic White	0.909	0.414–1.994
	Non-Hispanic Black	1.900	0.705–5.120
	Non-Hispanic Asian	0.880	0.344–2.251
	Other	2.337	0.336–16.247
Education	Less than HS		
	Some HS	1.122	0.380–3.315
	HS Graduate	0.773	0.265–2.255
	Some College	0.458	0.154–1.367
	College Graduate	1.053	0.294–3.766
Marital status	Married		
	Widowed	0.945	0.428–2.087
	Divorced	1.252	0.395–3.974
	Separated	2.246	0.590–8.546
	Never married	0.494	0.191–1.279
	Living with partner	1.422	0.481–4.208
Age	20–39		
	40–64	<b>4.207</b>	<b>1.526–11.600</b>
	65 and over	<b>41.765</b>	<b>15.179–114.918</b>
FIPR	Less than 130%		
	130–350%	0.340	0.213–0.543
	Over 350%	0.083	0.028–0.244
BMI	Normal weight		
	Underweight	4.941	0.585–41.738
	Overweight	1.368	0.706–2.649
	Obese	<b>2.172</b>	<b>1.268–3.721</b>
Serum cotinine	Below LLoD		
	Above LLoD	1.659	0.773–3.558
Alcohol consumption	Less than 12 drinks per year		
	12 or more drinks per year	0.438	0.228–0.840

Factors which are statistically significant at the  $\alpha=0.05$  level are highlighted in bold. *HS* high school. *LLoD* lower level of detection

The results of the dose–response study are shown in Table 5. The results indicate that of the arsenic species studied, only DMA showed a significant dose response trend in that respondents whose concentration fell in the 4th quartile were over 3 times as likely to have albuminuria. For cobalt, cesium, and tin, although there was a statistically significant difference between the below and above LLoD responses, the quartiles' odds ratios were not significantly different from each other. For barium, those in the 2nd, 3rd, and 4th quartiles had odds ratios that were significantly different from the below LLoD respondents, but the odds ratios associated with these quartiles were not different from each other and were less than one. For manganese, only the 2nd quartile was significantly different from the

other below LLoD respondents. The cesium results had all the odds ratios essentially equal to zero, which was a statistical artifact from the fact that only one respondent had urinary cesium levels below the lower limit of detection and therefore this result should not be taken as a valid response.

## Discussion

This study linked multiple metal exposures measured in urine with kidney impairment defined by albuminuria using ACR. The effect of multiple metal exposures on kidney function and other organs is complex and difficult to assess [47].



**Table 3** Arsenic and metal compound log<sub>10</sub> odds ratios (OR) and their 95% confidence intervals (CI) related to albuminuria from the multiple logit regression model that includes the main effects of the covariates for 19 species

Species	N	OR	95% CI
Arsenic compounds (µg/L)			
Arsenous acid	685	8.9	0.8–97.2
Arsenobetaine	670	1.7	0.5–5.5
DMA	981	<b>38.9</b>	<b>3.6–414.6</b>
MMA	777	<b>18.6</b>	<b>1.1–308.2</b>
Total arsenic	1363	3.2	0.9–11.9
Metal compounds (µg/L)			
Mercury	1369	0.9	0.3–3.2
Barium	1743	0.4	0.1–1.2
Cadmium	1653	<b>11.9</b>	<b>1.2–122.0</b>
Cobalt	1748	3.6	0.9–15.2
Cesium	1748	<b>17.0</b>	<b>2.7–105.8</b>
Molybdenum	1749	3.0	0.9–10.1
Manganese	504	3.0	0.8–11.9
Lead	1742	3.1	0.4–22.1
Antimony	1397	<b>10.7</b>	<b>2.2–51.3</b>
Tin	1638	0.8	0.4–1.8
Strontium	1749	0.6	0.1–2.3
Thallium	1741	0.9	0.1–8.7
Tungsten	1484	1.1	0.3–5.0
Uranium	1464	2.5	0.7–8.5

Effects that are statistically significant at  $\alpha=0.05$  are highlighted in bold. Adjusted for gender, ethnicity, education, marital status, age, FIPR, BMI, alcohol consumption, and cotinine. Arsenocholine and arsenic acid not included

End stage renal disease (ESRD) is one of the most dramatic health disparities in the US with rates in minorities ranging 1.5 to 4.0 times that of white counterparts. This can occur due to several mechanisms including clinical appropriateness and need, discrimination, biases and prejudice, stereotyping, and patient beliefs and preferences [48]. We determined a higher likelihood of albuminuria in non-Hispanic blacks. Crews et al. [49] found that race was not associated with CKD, but that African Americans had a much greater odds of advanced CKD defined as an eGFR < 30 mL/min/1.73 m<sup>2</sup>. Furthermore, a low social economic status (SES) was associated with a 59% greater odds of CKD. Low SES was associated with CKD in African Americans, but not in whites [49]. Our results supported a lower SES in relation to albuminuria in that a higher FIPR was associated with a lower likelihood for albuminuria.

Johnson et al. [50] found that among participants with CKD, a majority of participants were high school graduates, unemployed, female, unmarried, and/or earned less than or equal to \$10,000 per year. This analysis found no difference among gender, but determined that those who were divorced,

widowed, or separated had a higher likelihood of having albuminuria. In addition, Kramer et al. [51] calculated that the odds ratio of CKD in obese participants compared to those with an ideal BMI was 1.32. This study supported these findings in that a higher BMI resulted in a higher likelihood of having albuminuria. Nicotine exposure can cause exposures to lead, cadmium, arsenic and other nephrotoxic contaminants found in tobacco products. Cotinine is a biomarker for nicotine exposure. There was no significant association between albuminuria and cotinine.

### Urinary arsenic

Arsenic is categorized into inorganic and organic forms; humans can be exposed to both types via food or drink, or in occupational settings. Arsenobetaine is an organic form of arsenic and is considered nontoxic or less toxic. The inorganic forms of arsenic acids are toxic and go through a complex biotransformation mechanism of detoxification and methylation and are converted to MMA and DMA before excretion through the kidney in the urine [52].

Weidemann et al. [52] determined that total arsenic and DMA were associated with a lower eGFR, but there was no association between total arsenic or DMA and ACR. Hsueh et al. [53] found an association between total arsenic and CKD determined by GFR < 60. In addition, participants with a high urinary total arsenic or participants with a low percentage of DMA had a positive association with CKD. Participants with CKD had significantly higher urinary total arsenic and MMA levels, but lower DMA percentage than controls [53]. Furthermore, Jin et al. [54] determined that DMA increased linearly with eGFR, suggesting that reduced renal function is associated with reduced urinary DMA. In this analysis, ACR was used as a marker for albuminuria, rather than GFR, both DMA and MMA were positively associated with an increased ACR.

The exact mechanism of arsenic species and toxicity on kidney function is not fully understood. Studies in dogs' and humans' proximal tubular cell (PTC) lines showed that the PTC can metabolize arsenic by converting arsenate to arsenite which can damage the mitochondria in cells, inducing cellular toxicity [55, 56]. Experiments using mice have confirmed that increased levels of arsenite methyltransferase in the kidney can lead to arsenic toxicity [57]. Mouse studies also showed that oxidative stress plays a major role in nephrotoxicity from arsenic exposure [58]. Acute tubular toxicity and tubulointerstitial nephritis were observed from acute arsenic toxicity in humans [59]. Animal and human experiments established association among superoxide production, peroxidation, and damage in DNA from arsenic exposure [60]. Animal and human studies also found links between arsenic exposure and kidney damage which can increase ACR. Our study also supported the role of arsenic

**Table 4** Profile of the unweighted cotinine-normalized concentration of the various urinary arsenic and metal species in the 2015–2016 NHANES sample respondents over 20 years of age

Urinary species	Number below detection limit	Number above detection limit	Concentration quantiles				
			10% Q	25% Q	50% Q	75% Q	90% Q
Arsenous acid	1454	1640	0.0019	0.0030	0.0050	0.0081	0.0131
Arsenic acid	2997	97	0.0038	0.0055	0.0092	0.0135	0.0284
Arsenobetaine	1864	1230	0.0120	0.0239	0.0561	0.1534	0.4192
Arsenocholine	2560	534	0.0010	0.0017	0.0029	0.0061	0.0121
DMA	886	2208	0.0171	0.0252	0.0403	0.0684	0.1216
MMA	1370	1724	0.0024	0.0036	0.0059	0.0093	0.0148
Total Arsenic	0	3058	0.0255	0.0388	0.0637	0.1228	0.2833
Barium	8	2364	0.0031	0.0058	0.0110	0.0205	0.0360
Cadmium	132	2240	0.0007	0.0013	0.0024	0.0045	0.0078
Cobalt	2	2370	0.0020	0.0027	0.0039	0.0058	0.0094
Cesium	1	2371	0.1602	0.2391	0.3632	0.5356	0.7710
Molybdenum	0	2372	0.0214	0.0292	0.0400	0.0565	0.0791
Manganese	1678	694	0.0006	0.0008	0.0013	0.0023	0.0045
Lead	10	2362	0.0014	0.0022	0.0035	0.0058	0.0094
Antimony	447	1925	0.0003	0.0003	0.0005	0.0007	0.0012
Tin	145	2227	0.0018	0.0027	0.0048	0.0095	0.0203
Strontium	0	2372	0.3409	0.5913	0.9726	1.5133	2.2479
Thallium	10	2362	0.0008	0.0011	0.0015	0.0022	0.0031
Tungsten	330	2042	0.0003	0.0004	0.0007	0.0011	0.0020
Uranium	383	1989	0.0000	0.0000	0.0001	0.0001	0.0002
Mercury	1798	1282	0.0006	0.0010	0.0018	0.0036	0.0071

Q quantile

species, such as MMA and DMA, increasing ACR, which could lead to the development of CKD.

### Urinary metals

Limited studies have analyzed the effect of urinary cesium and kidney impairment. Jin et al. [54] determined that urinary cesium levels increased non-linearly with eGFR. In addition, urinary excretion rates of cesium significantly increased with increasing levels of eGFR, excretion rates were more sensitive in those with impaired renal function defined as  $GFR < 90 \text{ mL/min/1.73 m}^2$  [54]. The accumulation of cesium has been noted to have higher concentrations in the kidneys, with 85% of cesium eliminated in the urine [26]. A positive association between increased ACR and urinary cesium levels was found in this study, suggesting a link between CKD and cesium exposure.

Studies have shown that compounds containing antimony can have toxic effects on the kidney following chronic use [61]. Limited research has been conducted on antimony exposure in humans with CKD. In mice studies, antimony treatment was significantly linked to kidney dysfunction in addition to biochemical alterations in the architecture of the kidney. Furthermore, serum urea and creatinine, a measure of the GFR levels, were significantly increased in mice treated with antimony, suggesting that antimony had adverse

effects on the kidney [62]. A positive association was found between antimony and increased ACR, suggesting antimony may be linked to CKD.

Cadmium, lead, and mercury are heavy metals that are toxic to human health. High-level exposure to cadmium, lead, and mercury can cause damage to the renal system [10, 63–65]. Chronic exposure to cadmium, lead, and mercury can lead to deposition of these metals inside the body, the risk of adverse effects on the renal system with low-level exposure is unclear. A cross-sectional study conducted by Zhu et al. [66] with 2926 adults from the NHANES population showed that urinary and blood cadmium were significantly associated with increased ACR ( $\geq 30 \text{ mg/g}$ ), while urinary and blood lead and mercury were not associated with increased ACR. Furthermore, high level lead exposure is toxic to the renal system, low level exposure to lead and its adverse effects on the renal system are controversial [67]. Mujaj et al. [68] assessed for an association between ACR and eGFR and environmental lead exposure in 447 adult males. The study concluded that there was no significant association between lead exposure and renal impairment. A cross sectional study conducted by Grau-Perez et al. [69] in Spain with 1397 adults assessed for urinary albuminuria. The study concluded that urinary cadmium was associated with abnormal albuminuria. The findings from the above studies support our present findings with cadmium, lead,

**Table 5** Dose–response study odds ratios and 95% CI for urinary arsenic and metal species from the logit model that included only the main effects of the covariates

Species	1st quartile	2nd quartile	3rd quartile	4th quartile
Arsenous acid	OR 0.482 CI (0.232–1.000)	OR 0.545 CI (0.234–1.272)	OR 0.839 CI (0.334–2.108)	OR 0.927 CI (0.410–2.096)
Arsenic acid	OR 0.403 CI (0.045–3.590)	OR 4.281 CI (0.525–34.902)	OR 1.901 CI (0.292–12.374)	OR 0.447 CI (0.034–5.816)
Arsenobetaine	OR 0.645 CI (0.364–1.143)	OR 1.507 CI (0.650–3.497)	OR 0.925 CI (0.438–1.950)	OR 1.111 CI (0.430–2.871)
Arsenocholine	OR 0.402 CI (0.140–1.156)	OR 1.113 CI (0.295–4.194)	OR 0.763 CI (0.237–2.458)	OR 0.906 CI (0.372–2.206)
DMA	OR 0.752 CI (0.414–1.366)	OR 1.120 CI (0.536–2.340)	OR 1.074 CI (0.501–2.302)	<b>OR 3.237</b> <b>CI (1.200–8.734)</b>
MMA	OR 0.415 CI (0.214–0.804)	OR 0.640 CI (0.271–1.514)	OR 0.797 CI (0.486–1.305)	OR 1.064 CI (0.452–2.508)
Total arsenic		OR 1.427 CI (0.688–2.963)	OR 1.370 CI (0.631–2.973)	OR 1.822 CI (0.824–4.027)
Mercury	OR 0.409 CI (0.235–0.712)	OR 0.921 CI (0.418–2.029)	OR 1.145 CI (0.632–2.074)	OR 0.583 CI (0.268–1.273)
Barium	OR 0.188 CI (0.031–1.148)	<b>OR 0.129</b> <b>CI (0.021–0.779)</b>	<b>OR 0.128</b> <b>CI (0.022–0.752)</b>	<b>OR 0.098</b> <b>CI (0.015–0.615)</b>
Cadmium	OR 0.675 CI (0.148–3.071)	OR 0.815 CI (0.222–2.989)	OR 1.948 CI (0.550–6.901)	OR 1.609 CI (0.395–6.555)
Cobalt	<b>OR 13,585</b> <b>CI (2054–89,857)</b>	<b>OR 10,351</b> <b>CI (1602–66,861)</b>	<b>OR 13,098</b> <b>CI (2093–81,955)</b>	<b>OR 18,769</b> <b>CI (2960–119,001)</b>
Cesium	<b>OR 0.000</b> <b>CI (0.000–0.000)</b>	<b>OR 0.000</b> <b>CI (0.000–0.000)</b>	<b>OR 0.000</b> <b>CI (0.000–0.000)</b>	<b>OR 0.000</b> <b>CI (0.000–0.000)</b>
Molybdenum		OR 1.183 CI (0.525–2.665)	OR 1.502 CI (0.973–2.319)	OR 1.187 CI (0.748–1.883)
Manganese	OR 0.510 CI (0.260–1.003)	<b>OR 0.295</b> <b>CI (0.137–0.637)</b>	OR 1.000 CI (0.585–1.708)	OR 0.817 CI (0.450–1.485)
Lead	OR 0.401 CI (0.021–7.491)	OR 0.996 CI (0.060–16.625)	OR 0.873 CI (0.068–11.283)	OR 0.759 CI (0.046–12.610)
Antimony	OR 0.801 CI (0.330–1.944)	OR 0.915 CI (0.426–1.965)	OR 1.084 CI (0.510–2.303)	OR 1.469 CI (0.738–2.925)
Tin	<b>OR 3.825</b> <b>CI (1.103–13.266)</b>	<b>OR 4.719</b> <b>CI (1.518–14.666)</b>	<b>OR 6.073</b> <b>CI (1.756–21.009)</b>	OR 3.617 CI (0.962–13.603)
Strontium		OR 0.538 CI (0.252–1.150)	OR 0.780 CI (0.420–1.446)	OR 0.722 CI (0.343–1.524)
Thallium	OR 0.298 CI (0.037–2.395)	OR 0.306 CI (0.048–1.959)	OR 0.302 CI (0.030–3.028)	OR 0.335 CI (0.039–2.892)
Tungsten	OR 1.516 CI (0.605–3.800)	OR 1.890 CI (0.781–4.574)	OR 2.017 CI (0.915–4.444)	OR 1.803 CI (0.845–3.845)
Uranium	OR 0.861 CI (0.297–2.497)	OR 0.804 CI (0.409–1.578)	OR 1.084 CI (0.522–2.249)	OR 1.069 CI (0.391–2.921)

Odds ratios and 95% CI that are statistically significant at the  $\alpha=0.05$  level are highlighted in bold. Compounds with no entry in the 1st quartile had no respondents below LLoD and so the odds ratios for those species are relative to the 1st quartile respondents. *CI* confidence interval, *OR* odds ratio

and mercury. Results were consistent with the findings that cadmium was associated with abnormal ACR or albuminuria. Lead and mercury were not associated with albuminuria.

Cadmium is one of the most toxic pollutants in the environment; studies have reported damage to numerous organs and systems in humans and animals, including the kidneys. In rats, studies have shown that cadmium exposure causes enhanced lipid peroxidation and oxidative damage to the

cellular membranes [70]. Jacobo-Estrada et al. [71] determined that cadmium exposure in rats significantly raised albumin and vascular endothelial growth factor (VEGF) in amniotic fluid, while decreasing creatinine. In addition, antimony has been linked to renal dysfunction in mice [62]. In a study evaluating metals in cats, copper, zinc, and manganese were highest in the liver followed by the renal cortex and renal medulla. The occurrence of CKD also altered the storage of elements, with



higher cadmium in the liver and renal cortex in diseased cats [72].

Jayatilake et al. [73] found that uranium in sources of drinking water used by people with CKD were within normal limits. In addition, Kurttio et al. [74] found no evidence of renal damage in participants with uranium exposure in drinking water. No association was found among uranium in urine, water, hair, or toenails for 10 kidney toxicity indicators [74]. No association was found among kidney disease, measured by ACR, and urinary uranium in this study.

## Strengths and limitations

This study used the concentration of 19 different metals in urine and assessed the impact of metals on abnormal ACR, which is a biomarker for albuminuria. This is the first study that measured 19 metal co-exposures and ACR in adults by using the most recent NHANES dataset to our knowledge. Cotinine, which is a biomarker for nicotine exposure, was adjusted for. Furthermore, the analysis was adjusted for gender, ethnicity, education, marital status, age, FIPR, BMI, and alcohol consumption. The effect of all the stated demographic variables' exposure to metals and their association with ACR was analyzed. This study is one of the limited studies that analyzed nine demographic variables with multiple metal exposures and their association with ACR.

This study is a cross sectional design and therefore an inverse association cannot be ruled out. Albuminuria was measured by a single spot ACR in our study; there was no categorization between micro and macroalbuminuria and ACR was not measured over a period of 3 months to determine if the patient qualified for the diagnosis of CKD or not. The NHANES dataset only included the ACR measured at a single point in time, therefore there is no way to assess for interday or intraday variability of ACR and the results only apply to albuminuria rather than CKD. However, since albuminuria over 3 months can be classified as CKD, the results are suggestive of a possible link to CKD. Arsenocholine and arsenic acid were not included in our model. Once the data was cleaned, the remaining data was no longer distributed in such a way for a complete data analysis for these species. Therefore, the analysis began with 21 metals but only obtained results for 19. Also, the effects of interactions between the metals and CKD or interactions within the covariates were not examined. Possible associated conditions such as hypertension, diabetes, and cardiovascular disease were also not examined in this analysis.

## Conclusion

ACR, a measure of albuminuria, was associated with urinary DMA, MMA, cadmium, cesium, and antimony. This is a possible link between DMA, MMA, cadmium, cesium, and

antimony and CKD, suggesting that exposure to certain metals could put individuals at risk for CKD. Further research is needed to determine causation and understand the mechanism behind nephrotoxicity due to metal exposure.

**Author contributions** HHR conceptualized the study and contributed to the introduction and discussion. SH, M-M conducted data analysis and contributed to the statistical methods and results section of the paper. DN contributed to the methods section and drafting of the paper.

**Funding** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Data availability** NHANES data is secondary data provided by the CDC to the public [75].

**Code availability** R version 3.6.3, Upon request.

## Declarations

**Conflict of interest** The authors declare that they have no conflicts of interest.

**Ethical approval** This study uses only secondary data analyses without any personal information identified using statistical data from the NHANES website, no further ethical approval for conducting the present study is required.

**Consent to participate** This study uses only secondary data.

**Consent for publication** Consent was given by all authors.

## References

- Järup L (2003) Hazards of heavy metal contamination. *Br Med Bull* 68:167–182. <https://doi.org/10.1093/bmb/ldg032>
- Tchounwou PB, Yedjou CG, Patlolla AK, Sutton DJ (2012) Heavy metal toxicity and the environment. *Exp Suppl* 101:133–164. [https://doi.org/10.1007/978-3-7643-8340-4\\_6](https://doi.org/10.1007/978-3-7643-8340-4_6)
- Rahman HH, Yusuf KK, Niemann D, Dipon SR (2020) Urinary speciated arsenic and depression among US adults. *Environ Sci Pollut Res Int* 27(18):23048–23053. <https://doi.org/10.1007/s11356-020-08858-2>
- Chowdhury R, Ramond A, O'Keeffe LM et al (2018) Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis. *BMJ* 362:k3310. <https://doi.org/10.1136/bmj.k3310>
- Nigra AE, Ruiz-Hernandez A, Redon J, Navas-Acien A, Tellez-Plaza M (2016) Environmental metals and cardiovascular disease in adults: a systematic review beyond lead and cadmium. *Curr Environ Health Rep* 3(4):416–433. <https://doi.org/10.1007/s40572-016-0117-9>
- Satarug S, Moore MR (2004) Adverse health effects of chronic exposure to low-level cadmium in foodstuffs and cigarette smoke. *Environ Health Perspect* 112(10):1099–1103. <https://doi.org/10.1289/ehp.6751>
- Tellez-Plaza M, Guallar E, Howard BV et al (2013) Cadmium exposure and incident cardiovascular disease. *Epidemiology* 24(3):421–429. <https://doi.org/10.1097/EDE.0b013e31828b0631>

8. Tellez-Plaza M, Navas-Acien A, Menke A, Crainiceanu CM, Pastor-Barriuso R, Guallar E (2012) Cadmium exposure and all-cause and cardiovascular mortality in the US general population. *Environ Health Perspect* 120(7):1017–1022. <https://doi.org/10.1289/ehp.1104352>
9. Wild P, Bourgkard E, Paris C (2009) Lung cancer and exposure to metals: the epidemiological evidence. *Methods Mol Biol* 472:139–167. [https://doi.org/10.1007/978-1-60327-492-0\\_6](https://doi.org/10.1007/978-1-60327-492-0_6)
10. Soderland P, Lovekar S, Weiner DE, Brooks DR, Kaufman JS (2010) Chronic kidney disease associated with environmental toxins and exposures. *Adv Chronic Kidney Dis* 17(3):254–264. <https://doi.org/10.1053/j.ackd.2010.03.011>
11. Rahman HH, Niemann D, Singh D (2020) Arsenic exposure and association with hepatitis E IgG antibodies. *J Occup Environ Med* 8:111–122. <https://doi.org/10.4236/odem.2020.83009>
12. Reyes JL, Molina-Jijón E, Rodríguez-Muñoz R, Bautista-García P, Debray-García Y, Namorado M (2013) Tight junction proteins and oxidative stress in heavy metals-induced nephrotoxicity. *Biomed Res Int*. <https://doi.org/10.1155/2013/730789>
13. Stevens PE, Levin A (2013) Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med* 158(11):825–830. <https://doi.org/10.7326/0003-4819-158-11-201306040-00007>
14. Basi S, Fesler P, Mimran A, Lewis JB (2008) Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander? *Diabetes Care* 31(Suppl 2):S194–S201. <https://doi.org/10.2337/dc08-s249>
15. Toto RD (2004) Microalbuminuria: definition, detection, and clinical significance. *J Clin Hypertens (Greenwich)* 6(11 Suppl 3):2–7. <https://doi.org/10.1111/j.1524-6175.2004.4064.x>
16. CDC (2018a) National Health and Nutrition Examination Survey, 2015–2016 Data Documentation, Codebook, and Frequencies, Speciated Arsenics - Urine (UAS\_I). [https://www.cdc.gov/Nchs/Nhanes/2015-2016/UAS\\_I.htm](https://www.cdc.gov/Nchs/Nhanes/2015-2016/UAS_I.htm)
17. Glasscock RJ, Warnock DG, Delanaye P (2017) The global burden of chronic kidney disease: estimates, variability and pitfalls. *Nat Rev Nephrol* 13(2):104–114. <https://doi.org/10.1038/nrneph.2016.163>
18. Zheng L, Kuo CC, Fadrowski J, Agnew J, Weaver VM, Navas-Acien A (2014) Arsenic and chronic kidney disease: a systematic review. *Curr Environ Health Rep* 1(3):192–207. <https://doi.org/10.1007/s40572-014-0024-x>
19. Souweine JS, Corbel A, Rigothier C et al (2019) Interest of albuminuria in nephrology, diabetology and as a marker of cardiovascular risk. Intérêt de l'albuminurie en néphrologie, diabétologie et comme marqueur de risque cardiovasculaire. *Ann Biol Clin (Paris)* 77(1):26–35. <https://doi.org/10.1684/abc.2018.1402>
20. Lunyera J, Smith SR (2017) Heavy metal nephropathy: considerations for exposure analysis. *Kidney Int* 92(3):548–550. <https://doi.org/10.1016/j.kint.2017.04.043>
21. Fadrowski JJ, Navas-Acien A, Tellez-Plaza M, Guallar E, Weaver VM, Furth SL (2010) Blood lead level and kidney function in US adolescents: the third national health and nutrition examination survey. *Arch Intern Med* 170(1):75–82. <https://doi.org/10.1001/archinternmed.2009.417>
22. Ferraro PM, Costanzi S, Naticchia A, Sturniolo A, Gambaro G (2010) Low level exposure to cadmium increases the risk of chronic kidney disease: analysis of the NHANES 1999–2006. *BMC Public Health* 10:304. <https://doi.org/10.1186/1471-2458-10-304>
23. Kim NH, Hyun YY, Lee KB et al (2015) Environmental heavy metal exposure and chronic kidney disease in the general population. *J Korean Med Sci* 30(3):272–277. <https://doi.org/10.3346/jkms.2015.30.3.272> (**published correction appears in J Korean Med Sci. 2015 Apr;30(4):507. Rhu, Seungho [corrected to Ryu, Seungho]**)
24. Kim R, Rotnitsky A, Sparrow D, Weiss S, Wager C, Hu H (1996) A longitudinal study of low-level lead exposure and impairment of renal function. The Normative Aging Study. *JAMA* 275(15):1177–1181
25. Navas-Acien A, Tellez-Plaza M, Guallar E et al (2009) Blood cadmium and lead and chronic kidney disease in US adults: a joint analysis. *Am J Epidemiol* 170(9):1156–1164. <https://doi.org/10.1093/aje/kwp248>
26. Melnikov P, Zanoni LZ (2010) Clinical effects of cesium intake. *Biol Trace Elem Res* 135(1–3):1–9. <https://doi.org/10.1007/s12011-009-8486-7>
27. Jha V, Garcia-Garcia G, Iseki K et al (2013) Chronic kidney disease: global dimension and perspectives. *Lancet* 382(9888):260–272. [https://doi.org/10.1016/S0140-6736\(13\)60687-X](https://doi.org/10.1016/S0140-6736(13)60687-X) (**published correction appears in Lancet. 2013 Jul 20;382(9888):208**)
28. CDC (2017a) About the National Health and Nutrition Examination Survey. [https://www.cdc.gov/nchs/nhanes/about\\_nhanes.htm](https://www.cdc.gov/nchs/nhanes/about_nhanes.htm)
29. CDC (2019b) National Health and Nutrition Examination Survey, 2015–2016 Data Documentation, Codebook, and Frequencies, Albumin & Creatinine - Urine (ALB\_CR\_I). [https://www.cdc.gov/Nchs/Nhanes/2015-2016/ALB\\_CR\\_I.htm](https://www.cdc.gov/Nchs/Nhanes/2015-2016/ALB_CR_I.htm)
30. CDC (2018b) National Health and Nutrition Examination Survey, 2015–2016 Data Documentation, Codebook, and Frequencies, Arsenic - Total - Urine (UTAS\_I). [https://www.cdc.gov/Nchs/Nhanes/2015-2016/UTAS\\_I.htm](https://www.cdc.gov/Nchs/Nhanes/2015-2016/UTAS_I.htm)
31. CDC (2018c) National Health and Nutrition Examination Survey, 2015–2016 Data Documentation, Codebook, and Frequencies, Metals - Urine - Special Sample (UMS\_I). [https://www.cdc.gov/Nchs/Nhanes/2015-2016/UMS\\_I.htm](https://www.cdc.gov/Nchs/Nhanes/2015-2016/UMS_I.htm)
32. CDC (2018d) National Health and Nutrition Examination Survey, 2015–2016 Data Documentation, Codebook, and Frequencies, Mercury - Urine (UHG\_I). [https://www.cdc.gov/Nchs/Nhanes/2015-2016/UHG\\_I.htm](https://www.cdc.gov/Nchs/Nhanes/2015-2016/UHG_I.htm)
33. CDC (2017b) National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. <https://www.cdc.gov/nchs/nhanes/ContinuousNhanes/Default.aspx?BeginYear=2015>
34. CDC (2017c) National Health and Nutrition Examination Survey, 2015–2016 Data Documentation, Codebook, and Frequencies, Body Measures (BMX\_I). [https://www.cdc.gov/Nchs/Nhanes/2015-2016/BMX\\_I.htm](https://www.cdc.gov/Nchs/Nhanes/2015-2016/BMX_I.htm)
35. CDC (2017d) National Health and Nutrition Examination Survey, 2015–2016 Data Documentation, Codebook, and Frequencies, Demographic Variables and Sample Weights (DEMO\_I). [https://www.cdc.gov/Nchs/Nhanes/2015-2016/DEMO\\_I.htm](https://www.cdc.gov/Nchs/Nhanes/2015-2016/DEMO_I.htm)
36. CDC (2018e) National Health and Nutrition Examination Survey, 2015–2016 Data Documentation, Codebook, and Frequencies, Alcohol Use (ALQ\_I). [https://www.cdc.gov/Nchs/Nhanes/2015-2016/ALQ\\_I.htm](https://www.cdc.gov/Nchs/Nhanes/2015-2016/ALQ_I.htm)
37. CDC (2020a) Defining Adult Overweight and Obesity. <https://www.cdc.gov/obesity/adult/defining.html>
38. Jones MR, Tellez-Plaza M, Sharrett AR, Guallar E, Navas-Acien A (2011) Urine arsenic and hypertension in US adults: the 2003–2008 National Health and Nutrition Examination Survey. *Epidemiology* 22(2):153–161. <https://doi.org/10.1097/EDE.0b013e318207fdf2>
39. Buser MC, Ingber SZ, Raines N, Fowler DA, Scinicariello F (2016) Urinary and blood cadmium and lead and kidney function: NHANES 2007–2012. *Int J Hyg Environ Health* 219(3):261–267. <https://doi.org/10.1016/j.ijheh.2016.01.005>
40. Lumley T (2004) Analysis of complex survey samples. *J Stat Softw* 9(1):1–19. <https://doi.org/10.18637/jss.v009.i08>

41. Lumley T (2010) *Complex surveys: a guide to analysis using R*. Wiley
42. Lumley T (2020) Package ‘survey’: Analysis of Complex Survey Samples, version 4.0. <https://cran.r-project.org/web/packages/survey/survey.pdf>. Accessed 25 April 2021
43. R Core Team (2020) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org>. Accessed 25 April 2021
44. CDC (2019a) Module 3 examples - R code. [https://www.cdc.gov/nchs/data/tutorials/module3\\_examples\\_R.r](https://www.cdc.gov/nchs/data/tutorials/module3_examples_R.r)
45. Susmann H (2016) Package ‘RNHANES’: Facilitates Analysis of CDC NHANES, version 1.1.0. <https://cran.r-project.org/web/packages/RNHANES/RNHANES.pdf>. Accessed 25 April 2021
46. Prabhakaran S (2016) Package ‘InformationValue’: Performance Analysis and Companion Functions for Binary Classification Models, version 1.2.3. <https://cran.r-project.org/web/packages/InformationValue/InformationValue.pdf>. Accessed 25 April 2021
47. Jain RB (2019) Co-exposures to toxic metals cadmium, lead, and mercury and their impact on unhealthy kidney function. *Environ Sci Pollut Res Int* 26(29):30112–30118. <https://doi.org/10.1007/s11356-019-06182-y>
48. Norris K, Nissenson AR (2008) Race, gender, and socioeconomic disparities in CKD in the United States. *J Am Soc Nephrol* 19(7):1261–1270. <https://doi.org/10.1681/ASN.2008030276>
49. Crews DC, Charles RF, Evans MK, Zonderman AB, Powe NR (2010) Poverty, race, and CKD in a racially and socioeconomically diverse urban population. *Am J Kidney Dis* 55(6):992–1000. <https://doi.org/10.1053/j.ajkd.2009.12.032>
50. Johnson AE, Boulware LE, Anderson CA et al (2014) Perceived barriers and facilitators of using dietary modification for CKD prevention among African Americans of low socioeconomic status: a qualitative study. *BMC Nephrol* 15:194. <https://doi.org/10.1186/1471-2369-15-194>
51. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D (2005) Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. *Am J Kidney Dis* 46(4):587–594. <https://doi.org/10.1053/j.ajkd.2005.06.007>
52. Weidemann D, Kuo CC, Navas-Acien A, Abraham AG, Weaver V, Fadrowski J (2015) Association of arsenic with kidney function in adolescents and young adults: results from the National Health and Nutrition Examination Survey 2009–2012. *Environ Res* 140:317–324. <https://doi.org/10.1016/j.envres.2015.03.030>
53. Hsueh YM, Chung CJ, Shiu HS et al (2009) Urinary arsenic species and CKD in a Taiwanese population: a case-control study. *Am J Kidney Dis* 54(5):859–870. <https://doi.org/10.1053/j.ajkd.2009.06.016>
54. Jin R, Zhu X, Shrubsole MJ, Yu C, Xia Z, Dai Q (2018) Associations of renal function with urinary excretion of metals: evidence from NHANES 2003–2012. *Environ Int* 121(Pt 2):1355–1362. <https://doi.org/10.1016/j.envint.2018.11.002>
55. Ginsburg JM (1965) Renal mechanism for excretion and transformation of arsenic in the dog. *Am J Physiol* 208:832–840. <https://doi.org/10.1152/ajplegacy.1965.208.5.832>
56. Peraza MA, Carter DE, Gandolfi AJ (2003) Toxicity and metabolism of subcytotoxic inorganic arsenic in human renal proximal tubule epithelial cells (HK-2). *Cell Biol Toxicol* 19(4):253–264. <https://doi.org/10.1023/b:cbto.0000003970.60896.49>
57. Healy SM, Casarez EA, Ayala-Fierro F, Aposhian H (1998) Enzymatic methylation of arsenic compounds. V. Arsenite methyltransferase activity in tissues of mice. *Toxicol Appl Pharmacol* 148(1):65–70. <https://doi.org/10.1006/taap.1997.8306>
58. Sinha M, Manna P, Sil PC (2008) Arjunolic acid attenuates arsenic-induced nephrotoxicity. *Pathophysiology* 15(3):147–156. <https://doi.org/10.1016/j.pathophys.2008.03.001>
59. Prasad GV, Rossi NF (1995) Arsenic intoxication associated with tubulointerstitial nephritis. *Am J Kidney Dis* 26(2):373–376. [https://doi.org/10.1016/0272-6386\(95\)90660-6](https://doi.org/10.1016/0272-6386(95)90660-6)
60. Sasaki A, Oshima Y, Fujimura A (2007) An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. *Exp Hematol* 35(2):252–262. <https://doi.org/10.1016/j.exphem.2006.10.004>
61. Winship KA (1987) Toxicity of antimony and its compounds. *Adv Drug React Acute Poisoning Rev* 6(2):67–90
62. Tanu T, Anjum A, Jahan M et al (2018) Antimony-induced neurobehavioral and biochemical perturbations in Mice. *Biol Trace Elem Res* 186(1):199–207. <https://doi.org/10.1007/s12011-018-1290-5>
63. Ekong EB, Jaar BG, Weaver VM (2006) Lead-related nephrotoxicity: a review of the epidemiologic evidence. *Kidney Int* 70(12):2074–2084. <https://doi.org/10.1038/sj.ki.5001809>
64. Evans M, Elinder CG (2011) Chronic renal failure from lead: myth or evidence-based fact? *Kidney Int* 79(3):272–279. <https://doi.org/10.1038/ki.2010.394>
65. Johri N, Jacquillet G, Unwin R (2010) Heavy metal poisoning: the effects of cadmium on the kidney. *Biomaterials* 23(5):783–792. <https://doi.org/10.1007/s10534-010-9328-y>
66. Zhu XJ, Wang JJ, Mao JH, Shu Q, Du LZ (2019) Relationships of cadmium, lead, and mercury levels with albuminuria in US adults: results from the national health and nutrition examination survey database, 2009–2012. *Am J Epidemiol* 188(7):1281–1287. <https://doi.org/10.1093/aje/kwz070>
67. Rastogi SK (2008) Renal effects of environmental and occupational lead exposure. *Indian J Occup Environ Med* 12(3):103–106. <https://doi.org/10.4103/0019-5278.44689>
68. Mujaj B, Yang WY, Zhang ZY et al (2019) Renal function in relation to low-level environmental lead exposure. *Nephrol Dial Transplant* 34(6):941–946. <https://doi.org/10.1093/ndt/gfy279>
69. Grau-Perez M, Pichler G, Galan-Chilet I et al (2017) Urine cadmium levels and albuminuria in a general population from Spain: a gene-environment interaction analysis. *Environ Int* 106:27–36. <https://doi.org/10.1016/j.envint.2017.05.008>
70. Rogalska J, Pilat-Marcinkiewicz B, Brzóska MM (2011) Protective effect of zinc against cadmium hepatotoxicity depends on this bioelement intake and level of cadmium exposure: a study in a rat model. *Chem Biol Interact* 193(3):191–203. <https://doi.org/10.1016/j.cbi.2011.05.008>
71. Jacobo-Estrada T, Cardenas-Gonzalez M, Santoyo-Sánchez M et al (2016) Evaluation of kidney injury biomarkers in rat amniotic fluid after gestational exposure to cadmium. *J Appl Toxicol* 36(9):1183–1193. <https://doi.org/10.1002/jat.3286>
72. PaBlack N, Mainzer B, Lahrssen-Wiederholt M et al (2014) Liver and kidney concentrations of strontium, barium, cadmium, copper, zinc, manganese, chromium, antimony, selenium and lead in cats. *BMC Vet Res* 10:163. <https://doi.org/10.1186/1746-6148-10-163> (Published 2014 Jul 17)
73. Jayatilake N, Mendis S, Maheepala P, Mehta FR, CKDu National Research Project Team (2013) Chronic kidney disease of uncertain aetiology: prevalence and causative factors in a developing country. *BMC Nephrol* 14:180. <https://doi.org/10.1186/1471-2369-14-180>
74. Kurttio P, Harmoinen A, Saha H et al (2006) Kidney toxicity of ingested uranium from drinking water. *Am J Kidney Dis* 47(6):972–982. <https://doi.org/10.1053/j.ajkd.2006.03.002>
75. CDC (2020b) NHANES Questionnaires, Datasets, and Related Documentation. <https://www.cdc.gov/nchs/nhanes/ContinuousNhanes/Default.aspx?BeginYear=2015>

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.